EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, today announced that a late breaking abstract sponsored by the Company has been accepted for a poster presentation at the American Diabetes Association 67th Scientific Sessions in Chicago. The abstract, entitled “Results of a Randomized, Single-Dose, 2/3-Way Crossover Comparison Study of Intranasal Insulin Spray (Nasulin™) and Injectable Fast-Acting Insulin (Humalog®) in Normal Nonsmoking and Smoking Subjects,” will be included in the category of Clinical Therapeutics/New Technology – Insulin Delivery Systems and displayed Saturday, Sunday and Monday, June 23-25, 2007, in the General Poster Session in the Exhibit Hall.
